- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT02595957
Forskningsinitiativ for genomiske sekundære funn
The Genomic Services Research Program investigates the impact of returning medically-actionable secondary findings (SF) from genome and exome sequencing. This observational study examines how recipients understand these findings, communicate them to healthcare providers and family members, and adhere to recommended health actions over time.
Key objectives include:
- Assessing clinical utility of SF through healthcare actions and family communication patterns
- Evaluating penetrance of SF-related disorders in an unselected population
- Conducting bespoke phenotyping for selected participants at NIH facilities
The study involves 5,000 participants who have received SF through various NIH sequencing initiatives. Eligible participants include English- or Spanish-speaking individuals aged 1 month and older who have received SF results, with special considerations for minors, decisionally-impaired adults, and pregnant women.
Research focuses on four primary outcomes:
- Recipient responses and perceptions after SF disclosure
- Family-based positive predictive value of SF
- Adherence to medical recommendations
- Health impacts of receiving SF results
This long-term study (2014-2028) represents a significant effort by the National Human Genome Research Institute to understand the real-world implications of genomic medicine.
Kommende kliniske studier
-
NCT07826949Har ikke rekruttert ennåGlioma | Neoplasma i hjernen | Tilbakevendende høygradige gliomer
-
NCT07826962Har ikke rekruttert ennå
-
NCT07826975Har ikke rekruttert ennå
-
NCT07826988Har ikke rekruttert ennåSigdcellesykdom | Vaso-okklusiv krise
-
NCT07827001RekrutteringHjernekreft | CNS-kreft | Kreft i nervesystemet | Hjernemetastase
-
NCT07827027Har ikke rekruttert ennå
-
NCT07827040RekrutteringVoksne | Svagsyns digital assistanse | Synssvekkelser
-
NCT07827053Har ikke rekruttert ennåPankreas duktal adenokarsinom (PDAC)
-
NCT07827066Har ikke rekruttert ennåRøykeslutt | AI-agent | Early-Stage Cancer
-
NCT07827131Har ikke rekruttert ennå